VIM and lip and oral cavity carcinoma: This notion is supported by the increased levels of E-cadherin and lower levels of vimentin staining in both tongue tumors and lymph nodes observed in PXS-S1C-treated mice, and further supports the idea that LOXL2 significantly contributes to oral cancer development and that LOXL2 inhibitors may be of benefit in addressing oral cancer.